EurekAlert!

Progress and challenges in RET-targeted cancer therapy

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
Yahoo Finance

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Cure Today

Retevmo Approval the Beginning of Targeted Therapy for RET-Mutant Childhood Cancer

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population. The recent Food and Drug Administration (FDA) approval ...
Business Wire

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET ...

CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...
ascopubs.org

Clinical application of precision medicine among oncologists: A case study in RET-targeted therapy.

Life-cycle health technology assessment for precision oncology. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Pharmabiz

Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint

Eli Lilly and Company announced positive topline results from the phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary endpoint, ...